Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Minor fimbrial protein 1 (Mfa1) is a critical cell-surface adhesin of the periodontal pathogen Porphyromonas gingivalis (Daep et al., 2006, Infection and Immunity). It mediates the specific interspecies adherence between P. gingivalis and the commensal oral bacterium Streptococcus gordonii by binding to the SspB (Streptococcal surface protein B) protein (Demuth et al., 2001, Infection and Immunity). This interaction is a key early step in the colonization of the subgingival biofilm by P. gingivalis, which is a primary driver of chronic periodontitis (Hajishengallis et al., 2012, Nature Reviews Microbiology). The binding interface involves the recognition of a specific 27-amino acid sequence on SspB, known as the BAR (SspB Adherence Region) (Daep et al., 2008, Journal of Biological Chemistry). Therapeutic strategies targeting this interface, such as the BAR peptide or small-molecule inhibitors, aim to disrupt the incorporation of P. gingivalis into dental plaque. By preventing this attachment, these agents reduce the pathogen's ability to establish a niche and trigger the inflammatory destruction of periodontal tissues. Because this interaction is highly specific to the pathogen's integration into the biofilm, it represents a promising target for narrow-spectrum antimicrobial therapy that spares the healthy oral microbiome.
Competitive inhibition of the Mfa1-SspB interaction to prevent Porphyromonas gingivalis colonization and biofilm integration.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Minor fimbrial protein 1 (Mfa1) (Mfa1).